Crossmark

Accelerating evidence gathering and approval of precision medicine therapies: the FDA takes aim at rare mutations

Crossref DOI link: https://doi.org/10.1038/s41436-018-0099-0

Published Print: 2019-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Issa, Amalia M.

Thorogood, Adrian

Joly, Yann

Knoppers, Bartha M.
License Information

Text and Data Mining valid from 2019-03-01

Version of Record valid from 2021-11-24

Text and Data Mining valid from 2019-03-01
More Information

Article History

Received: 9 February 2018

Accepted: 7 June 2018

First Online: 10 July 2018

Change Date: 4 September 2018

Change Type: Correction

Change Details: In the original version of this Article, the affiliation details for Personalized Medicine & Targeted Therapeutics, USA were incorrectly given as Personalized Medicine & Targeted Therapeutics, University of the Sciences in Philadelphia, Philadelphia, Pennsylvania, USA. This has now been corrected in both the PDF and HTML versions of the Article.

Disclosure

: The authors declare no conflict of interest.